Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition
about
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenGenetic engineering with T cell receptorsOptimisations and Challenges Involved in the Creation of Various Bioluminescent and Fluorescent Influenza A Virus Strains for In Vitro and In Vivo ApplicationsBicistronic lentiviruses containing a viral 2A cleavage sequence reliably co-express two proteins and restore vision to an animal model of LCA1T-cell receptor gene therapy--ready to go viral?How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transferEngineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.Unbiased analysis of TCRα/β chains at the single-cell level in human CD8+ T-cell subsetsLongitudinal monitoring of Gaussia and Nano luciferase activities to concurrently assess ER calcium homeostasis and ER stress in vivoStrategies to genetically engineer T cells for cancer immunotherapy.Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes.Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture.Modeling initiation of Ewing sarcoma in human neural crest cells.The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes.A practical approach to T-cell receptor cloning and expression.Comparison of IRES and F2A-based locus-specific multicistronic expression in stable mouse lines.Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia.Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cellsGenome editing in mouse spermatogonial stem/progenitor cells using engineered nucleases.Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials.Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cellsIn vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.Optimisation of the foot-and-mouth disease virus 2A co-expression system for biomedical applications.Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections.Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cellsLentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells.Specific roles of each TCR hemichain in generating functional chain-centric TCR.Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variantsDual transgene expression in murine cerebellar Purkinje neurons by viral transduction in vivoNCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maSimultaneous Overexpression of Functional Human HO-1, E5NT and ENTPD1 Protects Murine Fibroblasts against TNF-α-Induced Injury In VitroEngineered cellular gene-replacement platform for selective and inducible proteolytic profiling.Functional Oxygen Sensitivity of Astrocytes.Recombinant AAV Vectors for Enhanced Expression of Authentic IgG.Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells.Processing and targeting of proteins derived from polyprotein with 2A and LP4/2A as peptide linkers in a maize expression system.Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model
P2860
Q24623215-AC2C8553-3AA2-4E64-BDF0-94FD0E9C93D4Q26995677-642C0626-F295-4613-97BB-D8A37578B2EDQ27301941-AF8DEAAC-3D40-4DD7-924C-57048791D103Q27336372-108F3050-5559-4845-AC08-3B26A3DFA66FQ28081611-2E312610-7AF3-4E46-85EC-34739D40FD18Q28727481-0BAEACA3-A45B-4EA0-A4DA-99757E0485E0Q30974719-3B36C9EE-7917-470A-8855-D3D971185A7EQ31072111-58C90B29-3250-4633-855E-D21635E21DDAQ33558795-62474C85-08A9-460C-A6D1-BE820485B764Q33655849-6FDE835D-F190-47E0-842C-9036D253A7ADQ33688441-7210C092-47B4-48FD-9583-C087DD5D1811Q33709279-D1811867-78AB-41B9-8171-B6A0A8025F20Q33894979-AB034F8C-94DC-4700-A698-0FC243790B43Q33987699-81F9A0BD-86A5-4458-8A03-84EC7D20883BQ34088001-B2C7F962-7130-47C0-BE90-9F4298FE5C4EQ34117035-BB2CB897-F750-4414-8D5B-54D6CFAF3D06Q34168766-F804B1D4-5275-4984-B873-B73F6BB89D1BQ34370215-C3A875DB-376F-4C69-AB89-738DFAD25BF5Q34542214-D77C1E6D-BB81-4EFE-A8D6-35A9708CB55FQ34678708-DF8EE704-7092-4332-9219-5176DD0C3CF7Q34760414-131FE182-16BE-49ED-925F-D377C03C4D5DQ34827147-2C757301-D4B6-4D85-9E2F-2E5918CA35C4Q34966685-5DECB81E-0187-4A7B-9596-CC35496561B1Q35080090-AD9476AB-D58F-417F-BF14-4CA190D61D6DQ35102451-617077E5-DA8A-4927-BB3F-551C1F0524D9Q35135031-2A5121CB-C6F2-40D9-BC31-F5AED2157601Q35145144-6CF7E31E-1E3D-4E5D-A3DD-5EA110C5D3A9Q35153765-2D4BEBA5-77AC-4F7B-B6D1-360672D2F44BQ35161543-B0F7A115-16C7-4EF3-B80F-C4DADB70473BQ35205495-AEC3152F-C6B0-4D04-A8C6-D69BDCB10B47Q35210473-B8CB1958-7540-4777-B4B4-A7E4B571D2F6Q35219552-34C6F428-9245-44E4-89FD-F1D86162B660Q35605318-AFDFF95B-9939-4AD2-A0AE-70870CD4E7CCQ35826059-63E43147-F4D8-446D-A4F0-79A181D6295EQ35845942-ADF32C73-2E93-4B6A-BC12-D692375A2E62Q35876793-744D6D2F-F654-450E-B347-7E119971B051Q36058890-6F8104AD-C7CD-45DF-9797-F0D9D49EC438Q36102927-7D03849F-A4A9-4D65-B498-574C9490E36EQ36328548-637A1B1D-4FA3-49AC-81D9-AB28E9960B7BQ36494531-6D69A725-9418-49E0-9497-17A48DE09BCD
P2860
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of optimal bicistr ...... robust tumor cell recognition
@en
Development of optimal bicistr ...... robust tumor cell recognition.
@nl
type
label
Development of optimal bicistr ...... robust tumor cell recognition
@en
Development of optimal bicistr ...... robust tumor cell recognition.
@nl
prefLabel
Development of optimal bicistr ...... robust tumor cell recognition
@en
Development of optimal bicistr ...... robust tumor cell recognition.
@nl
P2093
P2860
P50
P356
P1433
P1476
Development of optimal bicistr ...... robust tumor cell recognition
@en
P2093
R A Morgan
S A Rosenberg
P2860
P2888
P304
P356
10.1038/GT.2008.90
P577
2008-05-22T00:00:00Z